Related references
Note: Only part of the references are listed.Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)
Alexander C. J. van Akkooi et al.
ANNALS OF SURGICAL ONCOLOGY (2022)
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
E. A. Rozeman et al.
NATURE MEDICINE (2021)
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
Alexander M. Menzies et al.
NATURE MEDICINE (2021)
Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma
Joris L. Vos et al.
NATURE COMMUNICATIONS (2021)
EOMES is essential for antitumor activity of CD8+ T cells in chronic lymphocytic leukemia
Laura Llao-Cid et al.
LEUKEMIA (2021)
B cells and tertiary lymphoid structures promote immunotherapy response
Beth A. Helmink et al.
NATURE (2020)
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer A Systematic Review and Meta-analysis
Anup Kasi et al.
JAMA NETWORK OPEN (2020)
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
Alexander C. Huang et al.
NATURE MEDICINE (2019)
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium
Rodabe N. Amaria et al.
LANCET ONCOLOGY (2019)
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
Elisa A. Rozeman et al.
LANCET ONCOLOGY (2019)
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial
Georgina V. Long et al.
LANCET ONCOLOGY (2019)
Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma
M. T. Tetzlaff et al.
ANNALS OF ONCOLOGY (2018)
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
Rodabe N. Amaria et al.
LANCET ONCOLOGY (2018)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
P. M. Forde et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Rodabe N. Amaria et al.
NATURE MEDICINE (2018)
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
Christian U. Blank et al.
NATURE MEDICINE (2018)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Nadeem Riaz et al.
CELL (2017)
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
Jeffrey E. Gershenwald et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
Ana C. Anderson et al.
IMMUNITY (2016)
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Jing Liu et al.
CANCER DISCOVERY (2016)
Correlation of Pathologic Complete Response with Survival After Neoadjuvant Chemotherapy in Bladder Cancer Treated with Cystectomy: A Meta-analysis
Fausto Petrelli et al.
EUROPEAN UROLOGY (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients
Kimberly R. Jordan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Share Paper
